Physician profile
Carlos E Quezada
NPI 1437115698
$227,078.73
in general payments reported to CMS, 2019-2025
24 companies · $714 in 2025
The $714 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $10K · 2021: $62K · 2022: $39K · 2023: $72K · 2024: $7,155 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Travel and Lodging: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,433.83 |
| Travel and Lodging | $14,365.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $1,481.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $209,636.45 | 2019-2024 | Acessa Provu System |
| Hologic Sales and Service, LLC | $8,656.50 | 2020-2025 | Acessa Provu System |
| Astellas Pharma US INC | $4,000.00 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $2,427.31 | 2019-2020 | |
| Avanos Medical | $678.25 | 2020-2023 | On-Q* Pump and Accessories |
| Applied Medical Resources Corporation | $411.86 | 2021 | |
| Zimvie INC. | $319.71 | 2023 | |
| Abbvie INC. | $204.02 | 2019-2023 | |
| Gynesonics, INC. | $149.67 | 2021 | |
| Lupin INC. | $110.37 | 2020-2021 | |
| Radius Health, INC. | $107.27 | 2020-2023 | Tymlos |
| Myovant Sciences INC. | $92.24 | 2022 | |
| Sumitomo Pharma America, INC. | $58.14 | 2023 | Myfembree |
| Axonics, INC. | $47.22 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $30.98 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $26.51 | 2021 | |
| Amgen INC. | $22.35 | 2021 | |
| Baxter Healthcare | $19.89 | 2022 | |
| Evofem Biosciences, INC. | $18.91 | 2021 | |
| Pfizer INC. | $15.55 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.47 | 2022 | |
| Dysis Medical, INC. | $15.04 | 2021 | |
| Avion Pharmaceuticals | $13.60 | 2022 | |
| Organon LLC | $1.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Quezada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.